Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

Bo AhrénDepartment of Clinical Sciences, Lund University, Lund, SwedenAbstract: Inhibition of dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagonlike peptide-1 (GLP-1). This increases circulating levels of active GLP-1, stimulates insulin secretion and inhibits glucagon s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Ahren B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Glucagon-like peptide-1 dipeptidyl peptidase-4 type 2 diabetes sitagliptin treatment Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/c4c71a79f0684c539d5fe2472a069960
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c4c71a79f0684c539d5fe2472a069960
record_format	dspace
spelling	oai:doaj.org-article:c4c71a79f0684c539d5fe2472a0699602021-12-02T00:40:36ZUse of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin1178-7007https://doaj.org/article/c4c71a79f0684c539d5fe2472a0699602010-03-01T00:00:00Zhttps://www.dovepress.com/use-of-dpp-4-inhibitors-in-type-2-diabetes-focus-on-sitagliptin-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Bo AhrénDepartment of Clinical Sciences, Lund University, Lund, SwedenAbstract: Inhibition of dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagonlike peptide-1 (GLP-1). This increases circulating levels of active GLP-1, stimulates insulin secretion and inhibits glucagon secretion, which results in lowering of glucose levels and improvement of the glycemic control in patients with type 2 diabetes. This review summarizes experiences with DPP-4 inhibition in the treatment of type 2 diabetes, with a focus on sitagliptin. Sitagliptin has in several clinical studies been shown to improve metabolic control in type 2 diabetes, both when used as monotherapy and when used in combination with metformin, sulfonylurea, thiazolidinediones or insulin. The reduction in HbA1c is ≈0.6% to 1.0% from baseline levels of 7.5% to 8.7% over 6 to 12 months therapy. Sitagliptin has a favorable safety profile, is highly tolerable, and there is a minimal risk of hypoglycemia. Furthermore, sitagliptin is body weight neutral or induces a slight body weight reduction. Sitagliptin may be used in the early stages of type 2 diabetes in combination with metformin or other treatments in subjects with inadequate glycemic control on these treatments alone. Sitagliptin may also be used in monotherapy and, finally, sitagliptin may be used in combination with insulin in more advanced stages of the disease.Keywords: glucagon-like peptide-1, dipeptidyl peptidase-4, type 2 diabetes, sitagliptin, treatmentAhren BDove Medical PressarticleGlucagon-like peptide-1dipeptidyl peptidase-4type 2 diabetessitagliptintreatmentSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 3, Pp 31-41 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Glucagon-like peptide-1 dipeptidyl peptidase-4 type 2 diabetes sitagliptin treatment Specialties of internal medicine RC581-951
spellingShingle	Glucagon-like peptide-1 dipeptidyl peptidase-4 type 2 diabetes sitagliptin treatment Specialties of internal medicine RC581-951 Ahren B Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
description	Bo AhrénDepartment of Clinical Sciences, Lund University, Lund, SwedenAbstract: Inhibition of dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagonlike peptide-1 (GLP-1). This increases circulating levels of active GLP-1, stimulates insulin secretion and inhibits glucagon secretion, which results in lowering of glucose levels and improvement of the glycemic control in patients with type 2 diabetes. This review summarizes experiences with DPP-4 inhibition in the treatment of type 2 diabetes, with a focus on sitagliptin. Sitagliptin has in several clinical studies been shown to improve metabolic control in type 2 diabetes, both when used as monotherapy and when used in combination with metformin, sulfonylurea, thiazolidinediones or insulin. The reduction in HbA1c is ≈0.6% to 1.0% from baseline levels of 7.5% to 8.7% over 6 to 12 months therapy. Sitagliptin has a favorable safety profile, is highly tolerable, and there is a minimal risk of hypoglycemia. Furthermore, sitagliptin is body weight neutral or induces a slight body weight reduction. Sitagliptin may be used in the early stages of type 2 diabetes in combination with metformin or other treatments in subjects with inadequate glycemic control on these treatments alone. Sitagliptin may also be used in monotherapy and, finally, sitagliptin may be used in combination with insulin in more advanced stages of the disease.Keywords: glucagon-like peptide-1, dipeptidyl peptidase-4, type 2 diabetes, sitagliptin, treatment
format	article
author	Ahren B
author_facet	Ahren B
author_sort	Ahren B
title	Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
title_short	Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
title_full	Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
title_fullStr	Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
title_full_unstemmed	Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
title_sort	use of dpp-4 inhibitors in type 2 diabetes: focus on sitagliptin
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/c4c71a79f0684c539d5fe2472a069960
work_keys_str_mv	AT ahrenb useofdpp4inhibitorsintype2diabetesfocusonsitagliptin
_version_	1718403581728522240

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

Ejemplares similares